Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
Furst
D E
DE
David Geffen School of Medicine, UCLA-RM 32-59, Los Angeles, CA 90025, USA. defurst@mednet.ucla.edu
Keystone
E C
EC
Kirkham
B
B
Kavanaugh
A
A
Fleischmann
R
R
Mease
P
P
Breedveld
F C
FC
Smolen
J S
JS
Kalden
J R
JR
Burmester
G R
GR
Braun
J
J
Emery
P
P
Winthrop
K
K
Bresnihan
B
B
De Benedetti
F
F
Dörner
T
T
Gibofsky
A
A
Schiff
M H
MH
Sieper
J
J
Singer
N
N
Van Riel
P L C M
PL
Weinblatt
M E
ME
Weisman
M H
MH
D000069594:Abatacept; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy; D019317:Evidence-Based Medicine; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000627:therapeutic use; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D007376:Interleukin-2 / Q000037:antagonists & inhibitors; D009894:Opportunistic Infections / Q000139:chemically induced; D012216:Rheumatic Diseases / Q000188:drug therapy*; D000069283:Rituximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D018796:Immunoconjugates; D007155:Immunologic Factors; D007375:Interleukin-1; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D000069594:Abatacept